The ADRB2 blockers propranolol and ICI-118,551, as part of novel therapeutic strategies, have been shown to decrease the ROS content in ccRCC cells and act as anti-inflammatory drugs. This evidence concerns the gene ADRB2 and nonpapillary renal cell carcinoma.